Novo Nordisk A/S (NYSE:NVO) Shares Acquired by Wealthstream Advisors Inc.

Wealthstream Advisors Inc. boosted its holdings in Novo Nordisk A/S (NYSE:NVO) by 3.9% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The fund owned 3,185 shares of the company’s stock after buying an additional 120 shares during the quarter. Wealthstream Advisors Inc.’s holdings in Novo Nordisk A/S were worth $379,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of NVO. 1620 Investment Advisors Inc. acquired a new position in shares of Novo Nordisk A/S in the 2nd quarter valued at $25,000. Strategic Investment Solutions Inc. IL acquired a new stake in shares of Novo Nordisk A/S during the second quarter valued at approximately $25,000. Orion Capital Management LLC purchased a new stake in shares of Novo Nordisk A/S in the 1st quarter valued at approximately $26,000. Gilliland Jeter Wealth Management LLC boosted its stake in Novo Nordisk A/S by 200.0% in the 2nd quarter. Gilliland Jeter Wealth Management LLC now owns 180 shares of the company’s stock worth $26,000 after purchasing an additional 120 shares during the period. Finally, Halpern Financial Inc. grew its position in Novo Nordisk A/S by 113.0% during the 2nd quarter. Halpern Financial Inc. now owns 213 shares of the company’s stock worth $30,000 after purchasing an additional 113 shares in the last quarter. Institutional investors own 11.54% of the company’s stock.

Novo Nordisk A/S Price Performance

Shares of NVO opened at $106.93 on Thursday. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.75 and a current ratio of 0.94. The firm has a market cap of $479.83 billion, a PE ratio of 34.60, a PEG ratio of 1.29 and a beta of 0.42. The firm’s 50 day moving average price is $119.68 and its 200 day moving average price is $129.92. Novo Nordisk A/S has a twelve month low of $94.73 and a twelve month high of $148.15.

Wall Street Analysts Forecast Growth

Several analysts have recently commented on NVO shares. BMO Capital Markets decreased their target price on Novo Nordisk A/S from $160.00 to $156.00 and set an “outperform” rating for the company in a research report on Thursday, October 17th. Cantor Fitzgerald reissued an “overweight” rating and issued a $160.00 price target on shares of Novo Nordisk A/S in a research report on Wednesday, November 6th. Finally, StockNews.com raised shares of Novo Nordisk A/S from a “buy” rating to a “strong-buy” rating in a research report on Friday, November 1st. One investment analyst has rated the stock with a hold rating, six have given a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average target price of $144.50.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.